Valuation: Inventiva

Market Cap 999M 1.16B 933M 856M 1.61B 110B 1.64B 10.95B 4.3B 55.12B 4.34B 4.24B 182B P/E 2026 *
-5.74x
P/E 2027 * -5.27x
Enterprise Value 880M 1.02B 822M 754M 1.42B 96.82B 1.44B 9.64B 3.78B 48.53B 3.82B 3.74B 160B EV / Sales 2026 *
130x
EV / Sales 2027 * 3.69x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+11.87%
Current month+11.58%
1 month+13.67%
3 months-15.54%
6 months-20.75%
Current year+7.48%
1 week 3.58
Extreme 3.585
4.32
1 month 3.57
Extreme 3.57
4.32
Current year 2.88
Extreme 2.88
6.2
1 year 2.88
Extreme 2.88
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 76 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

General Counsel

25,000 0.0131%
1/10/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+11.87%+44.71%+21.14% 1.16B
+8.49%+20.55%+70.77%+103.07% 68.12B
-1.05%+4.57%+36.51%+65.25% 55.18B
-1.09%+32.96%+19.67%+509.20% 28.63B
+0.57%+18.61%+54.85%+4.95% 23.99B
+2.72%+3.41%-16.11%-12.04% 23.53B
-1.26%+7.12%+45.67%-23.17% 18.45B
-2.04%+10.42%+30.52%+626.21% 16.44B
-3.88%+16.98%+199.30%+350.94% 15.83B
+3.58%+1.96%+43.35%+162.22% 13.4B
Average +0.56%+11.65%+52.92%+180.78% 26.47B
Weighted average by Cap. +1.83%+13.09%+50.87%+161.13%

Financials

2026 *2027 *
Net sales 6.79M 7.85M 6.34M 5.82M 10.94M 747M 11.12M 74.41M 29.21M 375M 29.48M 28.84M 1.24B 117M 136M 110M 101M 189M 12.92B 192M 1.29B 505M 6.47B 510M 498M 21.4B
Net income -152M -176M -142M -130M -245M -16.73B -249M -1.67B -654M -8.38B -660M -646M -27.72B -103M -119M -96.41M -88.44M -166M -11.36B -169M -1.13B -444M -5.69B -448M -438M -18.82B
Net Debt -120M -138M -112M -102M -193M -13.15B -196M -1.31B -514M -6.59B -519M -507M -21.79B -567M -655M -529M -486M -913M -62.37B -928M -6.21B -2.44B -31.26B -2.46B -2.41B -103B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-08-10 4.240 +0.24% 42,183
26-08-07 €4.230 +5.09% 346,870
26-08-06 €4.025 +3.87% 439,051
26-08-05 €3.875 +3.75% 408,414
26-08-04 €3.735 -1.45% 613,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.230EUR
Average target price
9.634EUR
Spread / Average Target
+127.76%

Quarterly revenue - Rate of surprise